Developer docs
API playgroundTry for free, no card

Search company profiles

Elasmogen

Full company profile

uuid0002nhb

Namestring
Elasmogen
Legal namestring
Elasmogen Ltd
Websiteurl
elasmogen.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Elasmogen Ltd is a privately held, pre-clinical biopharmaceutical company headquartered at the Foresterhill Health Campus in Aberdeen, Scotland. It was spun out of the University of Aberdeen in February 2016 by Professor Caroline Barelle (CEO) and Professor Andy Porter (CTO), building on the soloMER platform originally developed at Aberdeen's Scottish Biologics Facility. The company develops humanised single-domain biologics (soloMERs) derived from shark Variable New Antigen Receptors (VNARs); at approximately 11 kDa these are the smallest naturally occurring binding domains and roughly 9% the size of a conventional antibody. The proprietary platform includes 100+ billion clone drug libraries, multi-valent formats (Quad-X, Quad-Y), the NDure albumin-binding half-life extension technology, and a soloMER Drug Conjugate (SDC) architecture in which a neutrophil elastase-cleavable linker enables inflammation-driven release of a localised small-molecule payload (e.g. JAK inhibitor) alongside biologic target engagement (e.g. TNFα blockade).

The company's lead asset is ELN28, a first-in-class dual-acting soloMER conjugate combining TNFα blockade with localised JAK inhibition, positioned for Hidradenitis Suppurativa — a chronic inflammatory skin disease with only three licensed therapies and clinical response in roughly 30% of patients on existing biologics. The wider pipeline covers ocular inflammation (ELN-21, ELN-22), solid-tumour oncology (ELN-11, ALM-401 bispecific EGFR/ROR1 ADC with Almac Discovery), and inflammatory bowel disease (via Intract Pharma oral delivery). The portfolio is protected by 25+ granted patents globally plus an exclusive licence to the University of Aberdeen's VNAR pipeline.

Elasmogen is pre-revenue commercially and monetises the platform through a mix of out-licensing (e.g. NDure licensed to ImmunoForge), co-development partnerships (Almac Discovery, Feldan, Amgen, Merck), and grant funding from UKRI, Innovate UK, Scottish Enterprise and the Scottish Government. Capital has been raised across multiple rounds from Deepbridge Capital, BGF, the Scottish National Investment Bank and Scottish Enterprise, with cumulative disclosed funding exceeding £9 million plus an £8M Series A in May 2022. End-customers are not end-patients but pharmaceutical and biotech partners who license assets for clinical development and commercialisation.

Short descriptiontext

Elasmogen is a pre-clinical Scottish biopharmaceutical company developing soloMERs, single-domain biologics derived from shark VNARs, with a lead dual-acting conjugate (ELN28) for Hidradenitis Suppurativa and a broader pipeline across ophthalmology, oncology and inflammatory disease, monetised via licensing and co-development partnerships with pharmaceutical and biotech companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAberdeen, United Kingdom
HQ citystring
Aberdeen
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-domain biologics, shark VNAR therapeutics, biologics drug discovery, antibody drug conjugates, half-life extension
Industry2 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Therapeutic Biologics / Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Elasmogen generates revenue through licensing agreements with pharmaceutical and biotech partners. Partners receive access to soloMER technology, NDure half-life extension, or specific therapeutic programs in exchange for upfront payments, development milestone payments, and royalties on product sales.

elasmogen.com
2Grant Funding
TypeSubscription Recurring
Description

The company receives grant funding from government bodies including Innovate UK, UKRI, Scottish Enterprise, and Scottish Government for specific research programs in COVID-19, oncology, and inflammatory diseases.

elasmogen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1soloMER
Description

Proprietary humanized single-domain biologics platform derived from shark VNARs, approximately 1/12 the size of antibodies.

elasmogen.com
+4 more records
Core offering1 text field

Elasmogen is a pre-clinical biopharmaceutical company developing soloMERs — proprietary humanized single-domain biologics derived from shark VNARs (Variable New Antigen Receptors) at approximately 11 kDa. The company creates precision therapeutics for immune-mediated inflammatory diseases, with lead candidate ELN28 (a dual-acting soloMER conjugate combining TNFα blockade and localized JAK inhibition for Hidradenitis Suppurativa). Elasmogen monetizes its platform through licensing agreements, co-development partnerships, and grant funding rather than direct product commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 10x more potent than existing therapies in laboratory settings
+4 more records
Product overview1 text field

Elasmogen is a biopharmaceutical company developing soloMER biologics based on VNAR technology derived from sharks. The core platform produces 11 kDa binding domains (9% of antibody size) enabling site-specific delivery, intracellular targeting, and superior tumor penetration. The lead product is ELN28, a first-in-class dual-acting soloMER conjugate combining TNFα blockade and JAK inhibition for Hidradenitis Suppurativa. The pipeline includes ELN-21/ELN-22 for ocular diseases, ELN-11 for oncology, NDure™ half-life extension technology, and Quad-X™/Quad-Y™ multi-valent formats. Collaborations include ALM-401 bispecific ADC (Almac Discovery), oral delivery solutions (Intract Pharma), and COVID-19 therapeutics (University of Minnesota). The company holds over 25 granted patents across US, Europe and other territories.

Product and service9 records
1ELN28
CategoryTherapeutic Biologics - Core Product
Description

First-in-class, dual-acting soloMER conjugate combining TNFα blockade with localized JAK inhibition for the treatment of Hidradenitis Suppurativa. Features a neutrophil elastase-cleavable linker for inflammation-driven payload release. Designed to deliver precision immunosuppression confined to diseased tissue.

2soloMER Platform
CategoryBiologics Platform Technology
Description

Proprietary biologics technology platform based on humanized single-domain VNAR antibodies derived from sharks. At 11 kDa (9% of antibody size), soloMERs are the smallest naturally occurring binding domains, enabling site-specific delivery and intracellular targeting. Licensed to pharma and biotech partners.

3ELN-21 and ELN-22
CategoryTherapeutic Biologics - Ophthalmology
Description

Next-generation soloMER biologics for topical treatment of ocular diseases including refractory or corticosteroid-resistant uveitis and macular degeneration. Designed to enable eye-drop delivery to the back of the eye, eliminating the need for intravitreal injection.

4ELN-11
CategoryTherapeutic Biologics - Oncology
Description

SoloMER drug conjugate for treatment of solid tumours, developed in partnership with Almac Discovery Ltd. Targets cancer-specific antigens with improved tumour penetration and cell-killing capabilities.

5NDure Half-life Extension Technology
CategoryEnabling Biologics Technology
Description

SoloMER-based albumin binder technology for extending serum half-life of therapeutic proteins. Enables rapid re-formatting and simple manufacturing while retaining high-specificity albumin binding. Licensed to ImmunoForge for use in therapeutic fusion proteins.

6Quad-X and Quad-Y Multi-valent Formats
CategoryBiologics Diagnostic & Therapeutic Formats
Description

Multi-valent soloMER formats with 4 binding sites (compared with an antibody's two) for increased sensitivity and specificity in diagnostic and therapeutic applications. Quad-X reformatting has demonstrated up to 50,000-fold enhancement in efficacy.

7ALM-401 Bispecific ADC
CategoryTherapeutic Biologics - Oncology ADC
Description

First-in-class bispecific antibody drug conjugate targeting EGFR/ROR1 for refractory lung cancer. Approximately half the size of a conventional ADC, designed for improved tumour penetration. Demonstrated excellent preclinical efficacy with sustained regressions in NSCLC PDX models. Developed in collaboration with Almac Discovery.

8COVID-19 VNAR Therapeutics
CategoryTherapeutic & Diagnostic Biologics - Infectious Disease
Description

Panel of novel, potent anti-COVID-19 Spike protein VNAR biologics identified through collaboration with the University of Minnesota. Candidates blocked infection at doses as low as 200 pM. Developed for both therapeutic and point-of-care diagnostic applications.

9VNAR Drug Libraries
CategoryBiologics Discovery Platform Asset
Description

Over 100 billion unique VNAR and soloMER drug libraries combining qualities of different shark species. From these libraries, new drug leads can be efficiently isolated to a range of drug targets using proprietary drug-engine technology.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-01
Description

Global license agreement for Soteria and Phloral oral delivery technologies for colonic delivery of therapeutic proteins from soloMER platform. Initially focused on inflammatory bowel disease treatment. Extended from 2020 research collaboration with option to expand for up to four additional targets.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-04-29
Description

Partnership with University of Aberdeen's Scottish Biologics Facility for Scottish Government COVID-19 research award of almost £1M. Elasmogen deployed soloMER technology platform to develop next generation point-of-care diagnostics for COVID-19.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-25
Description

Research partnership identifying novel anti-COVID-19 VNAR therapeutic candidates. Collaboration achieved identification of potent candidates blocking infection at doses as low as 200 pM. Initial funding from Chief Scientist Group, Scottish Government coordinated through University of Aberdeen.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-01-07
Description

License agreement for NDure half-life extension technology for use in two non-disclosed therapeutic fusion protein targets. ImmunoForge responsible for pre-clinical and clinical development, manufacturing and commercialisation. Elasmogen receives upfront payment plus future milestone and royalty payments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-08-06
Description

£2M joint Innovate UK funded program to develop VNAR-based oncology platform. Collaboration on soloMER-Drug-Conjugate targeting ROR1 for solid tumours has achieved total tumour regression in in vivo models for over 100 days. Partnership first established in 2015 for solid tumour treatment.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-05-09
Description

Research collaboration with Amgen combining Feldan's Shuttle peptide-based delivery platform with Elasmogen's soloMER technology for intracellular delivery of biologics to two undisclosed intracellular targets. Exclusive partnership established in 2016.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-05-09
Description

Research agreement with Feldan Therapeutics and Elasmogen to develop and deliver novel intracellular biologics. Collaboration utilizes Feldan Shuttle and soloMER technology to develop delivery system and binding domains for two undisclosed intracellular targets.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration in the area of bioprocessing. Partnership endorsed through Elasmogen's technology validation alongside collaborations with Almac, Amgen, and Feldan.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Licensee of Elasmogen's NDure half-life extension technology for therapeutic fusion proteins. Comparable as an emerging player using soloMER-derived technology and a real-world validation of Elasmogen's platform licensing model.

TypeBroad incumbent
Description

Sanofi-owned pioneer of Nanobodies — single-domain antibody fragments from camelids that are the closest commercial analog to Elasmogen's VNAR/soloMERs. Directly comparable as the leading benchmark for single-domain biologics, now generating blockbuster revenue (e.g., caplacizumab) within a major pharma portfolio.

TypeDirect peer
Description

UK-based developer of Humabody single-domain antibody fragments for T-cell engagers and immune oncology. Direct peer in single-domain biologics, sharing the same thesis that small binding domains unlock novel targets and tissue penetration advantages.

TypeBroad incumbent
Description

Commercial-stage immunology biotech whose VYVGART franchise leads the FcRn inhibitor class. Comparable as a successful antibody-format biotech in immune-mediated disease, though Argenx uses full-length antibodies rather than single-domain fragments.

TypeDirect peer
Description

Pre-clinical biotech developing VNAR-based therapeutics derived from sharks — essentially the same biological source as Elasmogen's soloMERs. Direct modality peer with overlapping CNS and inflammation indications and a similarly IP-driven licensing model.

TypeEmerging player
Description

Clinical-stage immunology and oncology biotech whose pipeline includes antibody formats targeting TNF and other inflammatory mediators. Comparable as a mid-stage peer competing for similar inflammation partnership and BD attention.

TypeEmerging player
Description

Elasmogen's £2M Innovate UK co-development partner on the ROR1 and bispecific EGFR/ROR1 ADC programs. Comparable as an emerging oncology-biologics platform and direct collaboration partner.

TypeEmerging player
Description

Clinical-stage bispecific antibody platform company whose former CBO (Jane Dancer) is now Chair of Elasmogen. Comparable as a single-domain/format-engineering biotech with overlapping board and strategic perspective on immune-mediated disease.

TypeBroad incumbent
Description

Major pharma with an active HS program and dual-cytokine inhibition approach (IL-17A/F). Comparable as a broad incumbent competing in the same HS indication where Elasmogen's ELN28 is positioned.

TypeDirect peer
Description

UK single-domain antibody discovery company using alternative scaffolds. Comparable as a peer in engineering small, stable binding domains for therapeutic and diagnostic applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elasmogen

Therapeutic Biologics / Biopharmaceuticalselasmogen.com

Elasmogen is a pre-clinical Scottish biopharmaceutical company developing soloMERs, single-domain biologics derived from shark VNARs, with a lead dual-acting conjugate (ELN28) for Hidradenitis Suppurativa and a broader pipeline across ophthalmology, oncology and inflammatory disease, monetised via licensing and co-development partnerships with pharmaceutical and biotech companies.

What Elasmogen does

Elasmogen Ltd is a privately held, pre-clinical biopharmaceutical company headquartered at the Foresterhill Health Campus in Aberdeen, Scotland. It was spun out of the University of Aberdeen in February 2016 by Professor Caroline Barelle (CEO) and Professor Andy Porter (CTO), building on the soloMER platform originally developed at Aberdeen's Scottish Biologics Facility. The company develops humanised single-domain biologics (soloMERs) derived from shark Variable New Antigen Receptors (VNARs); at approximately 11 kDa these are the smallest naturally occurring binding domains and roughly 9% the size of a conventional antibody. The proprietary platform includes 100+ billion clone drug libraries, multi-valent formats (Quad-X, Quad-Y), the NDure albumin-binding half-life extension technology, and a soloMER Drug Conjugate (SDC) architecture in which a neutrophil elastase-cleavable linker enables inflammation-driven release of a localised small-molecule payload (e.g. JAK inhibitor) alongside biologic target engagement (e.g. TNFα blockade).

The company's lead asset is ELN28, a first-in-class dual-acting soloMER conjugate combining TNFα blockade with localised JAK inhibition, positioned for Hidradenitis Suppurativa — a chronic inflammatory skin disease with only three licensed therapies and clinical response in roughly 30% of patients on existing biologics. The wider pipeline covers ocular inflammation (ELN-21, ELN-22), solid-tumour oncology (ELN-11, ALM-401 bispecific EGFR/ROR1 ADC with Almac Discovery), and inflammatory bowel disease (via Intract Pharma oral delivery). The portfolio is protected by 25+ granted patents globally plus an exclusive licence to the University of Aberdeen's VNAR pipeline.

Elasmogen is pre-revenue commercially and monetises the platform through a mix of out-licensing (e.g. NDure licensed to ImmunoForge), co-development partnerships (Almac Discovery, Feldan, Amgen, Merck), and grant funding from UKRI, Innovate UK, Scottish Enterprise and the Scottish Government. Capital has been raised across multiple rounds from Deepbridge Capital, BGF, the Scottish National Investment Bank and Scottish Enterprise, with cumulative disclosed funding exceeding £9 million plus an £8M Series A in May 2022. End-customers are not end-patients but pharmaceutical and biotech partners who license assets for clinical development and commercialisation.

Elasmogen firmographics

Firmographics
Name
Elasmogen
Legal name
Elasmogen Ltd
Website
https://elasmogen.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Elasmogen is a pre-clinical Scottish biopharmaceutical company developing soloMERs, single-domain biologics derived from shark VNARs, with a lead dual-acting conjugate (ELN28) for Hidradenitis Suppurativa and a broader pipeline across ophthalmology, oncology and inflammatory disease, monetised via licensing and co-development partnerships with pharmaceutical and biotech companies.
Ownership category
akta.pro rank

Elasmogen industry classification

Industry
Product category
Therapeutic Biologics / Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Single-domain biologics
  • Shark VNAR therapeutics
  • Biologics drug discovery
  • Antibody drug conjugates
  • Half-life extension

Where Elasmogen is headquartered

Location

Headquarters

HQ city
Aberdeen
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Elasmogen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: Elasmogen generates revenue through licensing agreements with pharmaceutical and biotech partners. Partners receive access to soloMER technology, NDure half-life extension, or specific therapeutic programs in exchange for upfront payments, development milestone payments, and royalties on product sales.
  2. Grant Funding: The company receives grant funding from government bodies including Innovate UK, UKRI, Scottish Enterprise, and Scottish Government for specific research programs in COVID-19, oncology, and inflammatory diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Elasmogen product offering

Product offering

Core offering

Elasmogen is a pre-clinical biopharmaceutical company developing soloMERs — proprietary humanized single-domain biologics derived from shark VNARs (Variable New Antigen Receptors) at approximately 11 kDa. The company creates precision therapeutics for immune-mediated inflammatory diseases, with lead candidate ELN28 (a dual-acting soloMER conjugate combining TNFα blockade and localized JAK inhibition for Hidradenitis Suppurativa). Elasmogen monetizes its platform through licensing agreements, co-development partnerships, and grant funding rather than direct product commercialization.

Product overview

Elasmogen is a biopharmaceutical company developing soloMER biologics based on VNAR technology derived from sharks. The core platform produces 11 kDa binding domains (9% of antibody size) enabling site-specific delivery, intracellular targeting, and superior tumor penetration. The lead product is ELN28, a first-in-class dual-acting soloMER conjugate combining TNFα blockade and JAK inhibition for Hidradenitis Suppurativa. The pipeline includes ELN-21/ELN-22 for ocular diseases, ELN-11 for oncology, NDure™ half-life extension technology, and Quad-X™/Quad-Y™ multi-valent formats. Collaborations include ALM-401 bispecific ADC (Almac Discovery), oral delivery solutions (Intract Pharma), and COVID-19 therapeutics (University of Minnesota). The company holds over 25 granted patents across US, Europe and other territories.

Differentiator

Problem solved

Functional benefit

Brands

  • soloMER: Proprietary humanized single-domain biologics platform derived from shark VNARs, approximately 1/12 the size of antibodies.
  • ELN28
  • NDure
  • Quad-X
  • Quad-Y

Products and services

  • ELN28 First-in-class, dual-acting soloMER conjugate combining TNFα blockade with localized JAK inhibition for the treatment of Hidradenitis Suppurativa. Features a neutrophil elastase-cleavable linker for inflammation-driven payload release. Designed to deliver precision immunosuppression confined to diseased tissue.
  • soloMER Platform Proprietary biologics technology platform based on humanized single-domain VNAR antibodies derived from sharks. At 11 kDa (9% of antibody size), soloMERs are the smallest naturally occurring binding domains, enabling site-specific delivery and intracellular targeting. Licensed to pharma and biotech partners.
  • ELN-21 and ELN-22 Next-generation soloMER biologics for topical treatment of ocular diseases including refractory or corticosteroid-resistant uveitis and macular degeneration. Designed to enable eye-drop delivery to the back of the eye, eliminating the need for intravitreal injection.
  • ELN-11 SoloMER drug conjugate for treatment of solid tumours, developed in partnership with Almac Discovery Ltd. Targets cancer-specific antigens with improved tumour penetration and cell-killing capabilities.
  • NDure Half-life Extension Technology SoloMER-based albumin binder technology for extending serum half-life of therapeutic proteins. Enables rapid re-formatting and simple manufacturing while retaining high-specificity albumin binding. Licensed to ImmunoForge for use in therapeutic fusion proteins.
  • Quad-X and Quad-Y Multi-valent Formats Multi-valent soloMER formats with 4 binding sites (compared with an antibody's two) for increased sensitivity and specificity in diagnostic and therapeutic applications. Quad-X reformatting has demonstrated up to 50,000-fold enhancement in efficacy.
  • ALM-401 Bispecific ADC First-in-class bispecific antibody drug conjugate targeting EGFR/ROR1 for refractory lung cancer. Approximately half the size of a conventional ADC, designed for improved tumour penetration. Demonstrated excellent preclinical efficacy with sustained regressions in NSCLC PDX models. Developed in collaboration with Almac Discovery.
  • COVID-19 VNAR Therapeutics Panel of novel, potent anti-COVID-19 Spike protein VNAR biologics identified through collaboration with the University of Minnesota. Candidates blocked infection at doses as low as 200 pM. Developed for both therapeutic and point-of-care diagnostic applications.
  • VNAR Drug Libraries Over 100 billion unique VNAR and soloMER drug libraries combining qualities of different shark species. From these libraries, new drug leads can be efficiently isolated to a range of drug targets using proprietary drug-engine technology.

Quantifiable outcome

  • 10x more potent than existing therapies in laboratory settings
  • +4 more outcomes

Companies that use Elasmogen

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Elasmogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Elasmogen partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Intract PharmacoreStrategic or Co-development Partner · 1 May 2020Global license agreement for Soteria and Phloral oral delivery technologies for colonic delivery of therapeutic proteins from soloMER platform. Initially focused on inflammatory bowel disease treatment. Extended from 2020 research collaboration with option to expand for up to four additional targets.
  • University of AberdeenminorStrategic or Co-development Partner · 29 April 2020Partnership with University of Aberdeen's Scottish Biologics Facility for Scottish Government COVID-19 research award of almost £1M. Elasmogen deployed soloMER technology platform to develop next generation point-of-care diagnostics for COVID-19.
  • University of MinnesotaminorStrategic or Co-development Partner · 25 January 2020Research partnership identifying novel anti-COVID-19 VNAR therapeutic candidates. Collaboration achieved identification of potent candidates blocking infection at doses as low as 200 pM. Initial funding from Chief Scientist Group, Scottish Government coordinated through University of Aberdeen.
  • ImmunoForgeminorOEM/ Whitelabel/ Licensing Partner · 7 January 2019License agreement for NDure half-life extension technology for use in two non-disclosed therapeutic fusion protein targets. ImmunoForge responsible for pre-clinical and clinical development, manufacturing and commercialisation. Elasmogen receives upfront payment plus future milestone and royalty payments.
  • Almac Discovery LtdcoreStrategic or Co-development Partner · 6 August 2018£2M joint Innovate UK funded program to develop VNAR-based oncology platform. Collaboration on soloMER-Drug-Conjugate targeting ROR1 for solid tumours has achieved total tumour regression in in vivo models for over 100 days. Partnership first established in 2015 for solid tumour treatment.
  • Feldan TherapeuticsminorStrategic or Co-development Partner · 9 May 2017Research collaboration with Amgen combining Feldan's Shuttle peptide-based delivery platform with Elasmogen's soloMER technology for intracellular delivery of biologics to two undisclosed intracellular targets. Exclusive partnership established in 2016.
  • Amgen IncminorStrategic or Co-development Partner · 9 May 2017Research agreement with Feldan Therapeutics and Elasmogen to develop and deliver novel intracellular biologics. Collaboration utilizes Feldan Shuttle and soloMER technology to develop delivery system and binding domains for two undisclosed intracellular targets.
  • Merck GroupminorStrategic or Co-development PartnerCollaboration in the area of bioprocessing. Partnership endorsed through Elasmogen's technology validation alongside collaborations with Almac, Amgen, and Feldan.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Elasmogen competitors and assessment

Company assessment

Emerging players

  • ImmunoForge: Licensee of Elasmogen's NDure half-life extension technology for therapeutic fusion proteins. Comparable as an emerging player using soloMER-derived technology and a real-world validation of Elasmogen's platform licensing model.
  • Compass Therapeutics: Clinical-stage immunology and oncology biotech whose pipeline includes antibody formats targeting TNF and other inflammatory mediators. Comparable as a mid-stage peer competing for similar inflammation partnership and BD attention.
  • Almac Discovery: Elasmogen's £2M Innovate UK co-development partner on the ROR1 and bispecific EGFR/ROR1 ADC programs. Comparable as an emerging oncology-biologics platform and direct collaboration partner.
  • F-star Therapeutics: Clinical-stage bispecific antibody platform company whose former CBO (Jane Dancer) is now Chair of Elasmogen. Comparable as a single-domain/format-engineering biotech with overlapping board and strategic perspective on immune-mediated disease.

Broad incumbents

  • Ablynx (Sanofi): Sanofi-owned pioneer of Nanobodies — single-domain antibody fragments from camelids that are the closest commercial analog to Elasmogen's VNAR/soloMERs. Directly comparable as the leading benchmark for single-domain biologics, now generating blockbuster revenue (e.g., caplacizumab) within a major pharma portfolio.
  • Argenx: Commercial-stage immunology biotech whose VYVGART franchise leads the FcRn inhibitor class. Comparable as a successful antibody-format biotech in immune-mediated disease, though Argenx uses full-length antibodies rather than single-domain fragments.
  • UCB (BIMZELX/bimekizumab): Major pharma with an active HS program and dual-cytokine inhibition approach (IL-17A/F). Comparable as a broad incumbent competing in the same HS indication where Elasmogen's ELN28 is positioned.

Direct peers

  • Crescendo Biologics: UK-based developer of Humabody single-domain antibody fragments for T-cell engagers and immune oncology. Direct peer in single-domain biologics, sharing the same thesis that small binding domains unlock novel targets and tissue penetration advantages.
  • Ossianix: Pre-clinical biotech developing VNAR-based therapeutics derived from sharks — essentially the same biological source as Elasmogen's soloMERs. Direct modality peer with overlapping CNS and inflammation indications and a similarly IP-driven licensing model.
  • Isogenica: UK single-domain antibody discovery company using alternative scaffolds. Comparable as a peer in engineering small, stable binding domains for therapeutic and diagnostic applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Elasmogen social profiles

Digital presence

Elasmogen compliance and trust

Trust signal

Compliance1 record

Elasmogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elasmogen leadership team

Management profile

Number of profiles

Profiles9 records

Elasmogen funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elasmogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elasmogen

What does Elasmogen do?

Elasmogen is a pre-clinical biopharmaceutical company developing soloMERs — proprietary humanized single-domain biologics derived from shark VNARs (Variable New Antigen Receptors) at approximately 11 kDa. The company creates precision therapeutics for immune-mediated inflammatory diseases, with lead candidate ELN28 (a dual-acting soloMER conjugate combining TNFα blockade and localized JAK inhibition for Hidradenitis Suppurativa). Elasmogen monetizes its platform through licensing agreements, co-development partnerships, and grant funding rather than direct product commercialization.

Is Elasmogen a public or private company?

Elasmogen is a private company. It is classified as venture growth investor backed and is currently operating.

When was Elasmogen founded?

Elasmogen was founded in 2016. It employs 11 to 50 people.

Where is Elasmogen based?

Elasmogen is headquartered in Aberdeen, United Kingdom, in the Europe region.

How does Elasmogen make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are grant Funding.

Who are Elasmogen's main competitors?

Emerging players on record are ImmunoForge, Compass Therapeutics, Almac Discovery and F-star Therapeutics. Broad incumbents are Ablynx (Sanofi), Argenx and UCB (BIMZELX/bimekizumab). Direct peers are Crescendo Biologics, Ossianix and Isogenica.

Does Elasmogen have an API?

No public API is recorded for Elasmogen.

What industry is Elasmogen in?

Elasmogen's product category is Therapeutic Biologics / Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Scotland NewsAberdeen: Elasmogen funding from Scottish National Investment Bank and BGFElasmogen, an Aberdeen-based biotech, raised funding led by BGF and Scottish National Investment Bank (SNIB) to advance its soloMER drug pipeline. The investment will support pre-clinical trials of its ROR1-targeting antibody drug conjugate, a market valued at $2.4 billion in 2019. Jane Dancer will join the board as non-executive director.ElasmogenBGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company ElasmogenElasmogen, an Aberdeen-based biopharmaceutical company, has secured £8 million in investment led by BGF and the Scottish National Investment Bank, with additional support from Scottish Enterprise. This funding will enable the company to continue developing its pipeline of next-generation biologics based on shark-derived soloMER technology through pre-clinical trials. The investment supports Elasmogen's efforts to advance treatments for solid-tumour cancers and inflammatory diseases, leveraging a platform originally developed at the University of Aberdeen.PR NewswireElasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partnersElasmogen Ltd, a biopharmaceutical company based in Aberdeen, Scotland, announced a breakthrough in identifying next-generation protein-based therapeutic candidates (VNARs) capable of blocking COVID-19 infections, achieved through collaboration with the University of Minnesota. The newly identified VNARs block infection in live viral assays at doses as low as 200 pM, comparable to the best reported antibodies, and are only one-tenth the size of human antibodies, potentially allowing delivery through nasal or throat administration rather than injections. Initial funding was provided by the Scottish Government's Chief Scientist Group and coordinated through the University of Aberdeen.PR NewswireElasmogen gibt eine Reihe neuartiger, wirksamer Anti-COVID-19-Therapiekandidaten bekannt, die in Zusammenarbeit mit US-Forschungspartnern identifiziert wurdenElasmogen Ltd, a biopharmaceutical company based in Aberdeen, Scotland, announced on January 25, 2021 a breakthrough in identifying novel VNAR biologics capable of blocking SARS-CoV-2 infections in live virus assays at doses as low as 200 ppm, comparable to the best-known antibodies. The research was conducted in collaboration with the University of Minnesota and funded by the Scottish Government's Chief Scientist Group, with the University of Aberdeen coordinating the work. The VNAR therapeutics are approximately one-tenth the size of conventional antibodies, potentially allowing nasal or throat administration instead of injections, and early computational modeling suggests they may remain effective against the Kent and South African variants.PR NewswireElasmogen annonce la création d'un panel de candidats thérapeutiques novateurs efficaces contre le COVID-19, identifiés en collaboration avec des partenaires de recherche américainsElasmogen Ltd, a Scottish biopharmaceutical company, announced in January 2021 a breakthrough in identifying next-generation VNAR protein therapeutics potentially effective against COVID-19, developed in partnership with the University of Minnesota and funded by the Scottish Government's Chief Scientist Office, coordinated by the University of Aberdeen. The VNAR proteins demonstrated viral blocking at doses as low as 200 pM — comparable to leading antibodies — while being ten times smaller, potentially allowing nasal or throat administration instead of injection. The company noted that a subset of patients who respond poorly to vaccines could benefit from alternative therapeutic approaches as global vaccination efforts continue.PR NewswireElasmogen anuncia concesiones de dos nuevas familias de patentes VNAR y soloMERElasmogen Ltd announced the granting of two new families of patents for its VNAR and soloMER products on December 10, 2020, enhancing its intellectual property position in multiple territories. These patents support Elasmogen's drug discovery platform, which focuses on humanized or desensitized VNAR proteins for therapeutic applications, especially in systemic therapy. The recent patent grants enable the development of new therapies, including applications for treating aggressive diseases like cancer and inflammation.PR NewswireElasmogen gibt Patentschutz für 2 neue VNAR- und soloMER-Patentfamilien bekanntElasmogen Ltd, a biopharmaceutical company based in Aberdeen, Scotland, announced it has received patent protection for two new patent families covering humanized or de-immunized VNAR proteins (soloMERs™) for therapeutic applications in multiple regions including the USA, Europe, Canada, Japan, China, and Australia. The patents support the company's drug development platform for systemic therapy with extended serum half-life, and validate Elasmogen's proprietary drug libraries containing over 100 billion individual VNARs and soloMERs. The company is leveraging these patents through commercial partnerships, including a collaboration with Almac Discovery Ltd on the cancer target ROR1, which achieved complete tumor regression in solid tumors for over 100 days in in-vivo models.PR NewswireElasmogen annonce l'octroi de 2 nouvelles familles de brevets pour le VNAR et le soloMERElasmogen Ltd, a Scottish biopharmaceutical company, announced the granting of two new patent families in multiple territories covering its soloMER™ drug discovery platform and the use of humanized or non-immunized VNAR proteins for therapeutic applications. The patents protect Elasmogen's proprietary technology including its libraries of over 100 billion unique VNAR and soloMER drugs derived from shark immune proteins. The company highlighted successful partnership results, including a collaboration with Almac Discovery Ltd that achieved complete tumor regression in solid tumor models for over 100 days.